5EU Hemophilia A and B Recombinant Factor Replacement Therapy Report 2016 - $2.08 Billion Drug Forecasts and Market Analysis to 2024 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024" report to their offering.

The total market for recombinant hemophilia treatment in the 5EU is expected to grow from approximately $2.08 billion in 2014 to $2.36 billion in 2024.

This growth will be driven by increasing rates of recombinant factor replacement therapies across the 5EU countries; in Italy and Spain in particular, where the current rate of prophylactic treatment is relatively low, an increasing proportion of adult patients are getting prophylactic treatments.

We expect moderate and high rates of adoption of the long-acting rFVIII and rFIX therapies, respectively, over the forecast period. However, our primary research indicates that the high annual cost of therapy is of great concern among physicians and regulators in Europe and therefore the opportunities for premium pricing for new therapies will be limited during the forecast period.

Scope

- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in 5EU from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Hemophilia A and B market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitive Assessment

5.3 Product Profiles - Hemophilia A

5.4 Product Profiles - Hemophilia B

5.5 Product Profiles - Hemophilia A and B with Inhibitors

6 Unmet Need and Opportunity

6.1 Overview

6.2 Opportunity Analysis

6.3 Unmet Needs Gap Analysis

7 Pipeline Assessment

7.1 Overview

7.2 Late-Stage Development Candidates - Hemophilia A

7.3 Late-Stage Development Candidates - Hemophilia B

7.4 Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents (Patients with Inhibitors)

7.5 Promising Drugs in Early-Stage Development

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/b66xzv/hemophilia_a_and

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Hematological Drugs